INBX Stock Overview

A clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. More details

INBX fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (0.1x) is below the US market (18.6x)

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 135.7% per year for the next 3 years

Does not have meaningful revenue ($2M)

Large one-off items impacting financial results

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Inhibrx Biosciences, Inc. Competitors

Compugen

NasdaqCM:CGEN

US$192.5m

Puma Biotechnology

NasdaqGS:PBYI

US$135.5m

Voyager Therapeutics

NasdaqGS:VYGR

US$229.7m

Rigel Pharmaceuticals

NasdaqGS:RIGL

US$367.1m

Price History & Performance

Summary of share price highs, lows and changes for Inhibrx Biosciences
Historical stock prices
Current Share Price	US$12.83
52 Week High	US$18.95
52 Week Low	US$10.80
Beta	0
1 Month Change	-5.94%
3 Month Change	-10.47%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-7.83%

Recent updates

Shareholder Returns

	INBX	US Biotechs	US Market
7D	-5.4%	-4.8%	-0.5%
1Y	n/a	-3.2%	21.1%

Return vs Industry: Insufficient data to determine how INBX performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how INBX performed against the US Market.

Price Volatility

Is INBX's price volatile compared to industry and market?
INBX volatility
INBX Average Weekly Movement	8.1%
Biotechs Industry Average Movement	11.3%
Market Average Movement	5.9%
10% most volatile stocks in US Market	18.2%
10% least volatile stocks in US Market	3.0%

Stable Share Price: INBX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: INBX's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2024	173	Mark Lappe	inhibrx.com

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

Inhibrx Biosciences, Inc. Fundamentals Summary

How do Inhibrx Biosciences's earnings and revenue compare to its market cap?
INBX fundamental statistics
Market cap	US$181.24m
Earnings (TTM)	US$1.73b
Revenue (TTM)	US$1.57m

0.1x

P/E Ratio

118.4x

P/S Ratio

Is INBX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INBX income statement (TTM)
Revenue	US$1.57m
Cost of Revenue	US$190.96m
Gross Profit	-US$189.39m
Other Expenses	-US$1.92b
Earnings	US$1.73b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	119.39
Gross Margin	-12,078.57%
Net Profit Margin	110,218.75%
Debt/Equity Ratio	0%

How did INBX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/12 08:40
End of Day Share Price	2025/02/12 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Inhibrx Biosciences, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Michael Yee	Jefferies LLC
Reni Benjamin	JMP Securities